UNSPSC 51171964: Sufotidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C20H31N5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56B0591Y76, chemically known as 1-(m-(3-((1-methyl-3-((methylsulfonyl)methyl)-1h-1,2,4-triazol-5-yl)amino)propoxy)benzyl)piperidine but generally known as sufotidine, which bears US NIH Compound Identifier 71763. European Medicines Agency schedules Sufotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10673MIG.

UNSPSC 51171964 Sufotidine is a Commodity code that, based on recent state and local solicitation activity, does not align with actual procurement under this pharmaceutical designation. The three recent opportunities posted under or proximate to this code—a drug testing services RFP from Collin County, a pharmacy benefit program RFI from Texas HHS, and a multistate cooperative pharmaceutical and OTC products RFP from MMCAP—involve specimen collection, drug screening and confirmation testing, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution respectively. None of these solicitations explicitly reference sufotidine, a specific pharmaceutical compound. The code appears to have been applied inconsistently or incorrectly to the Collin County and MMCAP procurements, which involve commodity purchasing of testing services and generic drug inventory rather than a branded or generic sufotidine product line.

The issuing bodies span state health and human services agencies, county criminal justice departments, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department posted RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, with no formal award timeline or budget identified at the exploratory stage. MMCAP, administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Recent activity concentrates in Texas and the Upper Midwest, though the code itself shows limited coherence as applied to actual pharmaceutical procurement.